Related Experiment Video
Updated: Jul 15, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Association of tumor necrosis factor polymorphisms with Guillain-Barré syndrome
1Second Hospital of Hebei Medical University, Shijiazhuang, PR China.
Abstract:
It has been reported that the tumor necrosis factor (TNF)alpha promoter polymorphism is associated with autoimmune disease and inflammatory disease. It has also been claimed that this polymorphism may affect TNFalpha expression. We investigated the TNFalpha -308 polymorphism and TNFalpha levels in 79 unrelated Chinese patients with Guillain-Barré syndrome (GBS) and 78 healthy controls using PCR-RFLP and ELISA assay. Patients with GBS were divided into 2 subgroups, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), based on electrophysiological information. We found that the TNFalpha2 allele was associated with increased risk of GBS (OR = 1.876, 95% CI = 1.144-3.075, p = 0.008), particularly for AMAN, the main subtype (OR = 2.914, 95% CI = 1.412-6.015, p = 0.004), but there was no association between TNFalpha polymorphism and AIDP. We also found that carriers of the TNFalpha2 allele had significantly higher TNFalpha2 levels than TNFalpha1 homozygotes (p < 0.05). These data indicate that TNFalpha promoter polymorphism is responsible for susceptibility to GBS, especially to AMAN. The TNFalpha2 allele is associated with higher levels of TNFalpha.
More Related Videos
07:30A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu